Eliaz Therapeutics

Eliaz Therapeutics is developing XGAL‑3®, an advanced extracorporeal apheresis device designed to selectively remove Galectin‑3 from the bloodstream. The company targets life-threatening inflammatory conditions, primarily sepsis and sepsis-induced acute kidney injury. The technology has received FDA Breakthrough Device Designation and NIH grant support but has not yet entered clinical trials as of early 2025. Preclinical data suggest that removing Galectin‑3 may reduce inflammation, protect against immune dysregulation, prevent organ dysfunction, and improve outcomes in ICU patients with sepsis or AKI. The company holds over 60 patents across 34 countries related to this approach.